 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910111213...1415» |
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
LARGER THAN LARGE LEFT ATRIAL MYXOMA (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_2398;
Management requires careful consideration of each case to prevent embolic shower. The presence of the LA myxoma was unknown and the patient was given tenecteplase on admission.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, Head-to-Head: Intravenous tenecteplase compared with alteplase for acute ischemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. (Pubmed Central) - Dec 29, 2022
The presence of the LA myxoma was unknown and the patient was given tenecteplase on admission. No abstract available
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Is Tenecteplase a Viable Alternative to Alteplase in the Treatment of Acute Ischemic Stroke? (Pubmed Central) - Dec 24, 2022
No abstract available No abstract available
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Trail Toward Tenecteplase. (Pubmed Central) - Dec 24, 2022
No abstract available No abstract available
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Tenecteplase and Alteplase for Thrombolysis of Acute Ischemic Stroke within 4.5 Hours: An Efficacy and Safety Study. (Pubmed Central) - Dec 24, 2022
This study showed a comparable efficacy and safety profile of alteplase and TNK in thrombolysis of AIS throughout the 4.5 hours window period. Moreover, the ease of administration and better pharmacodynamic properties favors tenecteplase.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Early recanalization with intravenous thrombolysis before mechanical thrombectomy: considerations to explore with tenecteplase. (Pubmed Central) - Dec 24, 2022
Moreover, the ease of administration and better pharmacodynamic properties favors tenecteplase. No abstract available
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. (Pubmed Central) - Dec 23, 2022
P3
The number of symptomatic haemorrhages and any intracranial haemorrhages in both treatment groups was similar to findings from previous trials of wake-up stroke patients selected using advanced imaging. Current evidence does not support treatment with tenecteplase in patients selected with non-contrast CT.
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial completion date: STREAM-2: STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction (clinicaltrials.gov) - Dec 22, 2022
P4, N=609, Active, not recruiting, Sponsor: KU Leuven
Current evidence does not support treatment with tenecteplase in patients selected with non-contrast CT. Trial completion date: Nov 2022 --> Oct 2023
- ||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Enrollment closed: TIMELESS: Tenecteplase in Stroke Patients Between 4.5 and 24 Hours (clinicaltrials.gov) - Dec 21, 2022
P3, N=456, Active, not recruiting, Sponsor: Genentech, Inc.
Trial completion date: Nov 2022 --> Oct 2023 Recruiting --> Active, not recruiting
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P3 trial: Intra-arterial Tenecteplase During First Thrombectomy Attempt for Acute Stroke (BRETIS-TNK II) (clinicaltrials.gov) - Dec 20, 2022
P3, N=372, Not yet recruiting, Sponsor: General Hospital of Shenyang Military Region
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P3 trial: Improving Neurological Outcome for Acute Basilar Artery Occlusion With Sufficient Recanalization After Thrombectomy by Intraarterial Tenecteplase (INSIST-IT) (clinicaltrials.gov) - Dec 20, 2022
P3, N=228, Not yet recruiting, Sponsor: General Hospital of Shenyang Military Region
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P2/3 trial: Rescue Thrombolysis for Medium Vessel Occlusion (RESCUE-TNK) (clinicaltrials.gov) - Dec 20, 2022
P2/3, N=80, Not yet recruiting, Sponsor: General Hospital of Shenyang Military Region
- ||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Here's the result from the TWIST trial, link is available for reading in the Lancet Neurology for 50 days. Spoiler alert: 0,25 mg/kg, max 25 mg tenecteplase does not improve outcome in wake-up stroke (selected with non-contrast CT of the brain). https://t.co/eCDINM0a1k (Twitter) - Dec 20, 2022
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
After a quick read, this should be interpreted with extreme caution. Several issues: 1. Comparatively extremely low numbers for tenecteplase compared to alteplase 2. No info of LKW to treatment time 3. No info regarding symptomatic vs asymptomatic ICH 4. No info on dose used 1/2 (Twitter) - Dec 12, 2022
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, Real-world evidence: Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States. (Pubmed Central) - Dec 10, 2022
Recruiting --> Active, not recruiting In an analysis of real-world data, IV TNK was associated with higher rates of intracranial hemorrhage compared with IV alteplase in patients with acute ischemic stroke who did not undergo thrombectomy.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis: Insights from the TETRIS registry. (Pubmed Central) - Dec 9, 2022
In the multivariable analysis, tenecteplase was significantly associated with functional independence (OR 1.68, 95% CI 1.15-2.48, p < 0.01), but not with PH (OR 0.68, 95% CI 0.41-1.12, p = 0.13). Switch from alteplase to tenecteplase reduced process times and may improve functional outcome, with similar safety profile.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New trial: DISTAL-IVT: Early Recanalization After Intravenous Thrombolysis With Tenecteplase Versus Alteplase in Distal Vessel Occlusion Strokes (clinicaltrials.gov) - Dec 2, 2022
P=N/A, N=175, Not yet recruiting, Sponsor: Centre Hospitalier Sud Francilien
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Trial initiation date: TECNO: Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions (clinicaltrials.gov) - Nov 30, 2022
P3, N=156, Not yet recruiting, Sponsor: University Hospital Inselspital, Berne
Switch from alteplase to tenecteplase reduced process times and may improve functional outcome, with similar safety profile. Initiation date: Sep 2022 --> Dec 2022
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: Tenecteplase Compared to Alteplase for Patients With Large Vesel Oclusion Suspicion Before Thrombectomy (clinicaltrials.gov) - Nov 25, 2022
P3, N=500, Recruiting, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal, HEOR: Tenecteplase in managing acute ischemic stroke: a long-term cost-utility analysis in Iran. (Pubmed Central) - Nov 25, 2022
Moreover, the base case results were strongly confirmed by deterministic and probabilistic sensitivity analysis. Base-case and sensitivity analysis showed that TNK is the dominant strategy compared to ALT for the management of AIS patients.
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, enoxaparin sodium / Generic mfg.
Rv dysfunction alone is a soft indication for lysis - can use tenecteplase and then switch to clexane for 5D/“. Alternatively only clexane (Twitter) - Nov 23, 2022
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Tenecteplase versus alteplase before mechanical thrombectomy: experience from a US healthcare system undergoing a system-wide transition of primary thrombolytic. (Pubmed Central) - Nov 23, 2022
The higher spontaneous recanalization rates with TNK are striking. Additional studies are required to investigate whether TNK is superior to TPA in LVO AIS.
- | Meforex (recombinant human TNK tissue-type plasminogen activator) / CSPC Pharma, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P4 trial: ANGEL-TNK: Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization (clinicaltrials.gov) - Nov 22, 2022
P4, N=256, Not yet recruiting, Sponsor: Beijing Tiantan Hospital
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: In acute ischemic stroke, early IV tenecteplase was noninferior to alteplase for excellent functional outcome. (Pubmed Central) - Nov 18, 2022
2022;400:161-9. 35779553.
- ||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
🔔New @WorldStrokeEd Paper of The Month (November edition) on 'The Evolving Therapeutic Landscape of Acute Stroke Care: the addition of #Tenecteplase to our arsenal' by Dr. Prof. @gsaposnik. 👇https://t.co/ayE0Btft2U (Twitter) - Nov 15, 2022
- |||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
HEOR: Great discussion by @bijoymenon @gsaposnik @brianhb @WorldStrokeOrg on the nuances of @ActRrct and tenecteplase for #stroke, important economic considerations💰, and future of acute stroke trials and pushing the boundaries of thrombolysis #neurotwitter https://t.co/3FtJyDz1AZ (Twitter) - Nov 14, 2022
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
TPA or TNK: Making the Choice when Time Is Brain (Mandalay Bay South Convention Center, Oceanside C, Level 2) - Nov 12, 2022 - Abstract #ASHP2022ASHP_199;
Contrast alteplase and tenecteplase as therapeutic options in ischemic stroke management. Compose an organizational transition from alteplase to tenecteplase.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Roundtable and Poster Session: Critical Care (Mandalay Bay South Convention Center, Bayside B, Level 1) - Nov 12, 2022 - Abstract #ASHP2022ASHP_71;
Compose an organizational transition from alteplase to tenecteplase. Hosted by the Section of Clinical Specialists and Scientists Discussion Topics: Barbiturates vs. Benzodiazepines for alcohol withdrawal Alteplase vs. tenecteplase for acute ischemic stroke Things that don’t really cause AKI: Vanco + piperacillin and tazobactam injection, IV contrast Balancing rounding (clinical work) with administrative responsibilities
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
tPA vs. TNK, Amp-C and SGLT2 inhibitors! An Alphabet Soup of Therapeutic Updates (Mandalay Bay South Convention Center, South Seas F, Level 3) - Nov 12, 2022 - Abstract #ASHP2022ASHP_24;
Cite the recent updates regarding the use of SGLT2 inhibitors for the management of heart failure. Summarize the 2021 guideline on the treatment of AmpC β-lactamase producing Enterobacterales.
- Aggrastat (tirofiban) / Correvio, Medicure
USE OF INTRAVENOUS TIROFIBAN IN LACUNAR STROKES BEYOND 4 ½ HRS (GALLERY) - Nov 7, 2022 - Abstract #WSC2022WSC_1564;
Background and Aims: The only evidence based therapies for Lacunar strokes are Intra Venous thrombolysis with Alteplase / Tenecteplase upto 4 ½ hrs and oral aspirin within 48 hrs. IV Tirofiban is safe and effective in patients with lacunar strokes presenting beyond window period for IVT, however RCT with large number of patients is required.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
RANDOMIZATION TO ENDOVASCULAR TREATMENT ALONE OR PRECEDED BY SYSTEMIC THROMBOLYSIS WITH TENECTEPLASE IN ACUTE ISCHEMIC STROKE DUE TO LARGE INTRACRANIAL VESSEL OCCLUSION TRIAL (RESILIENT DIRECT-TNK) (GALLERY) - Nov 7, 2022 - Abstract #WSC2022WSC_1540;
Furthermore, Other trials have suggested that IV tenecteplase (TNK), when administered before MT in LVO AIS patients, results in higher recanalization rates and better clinical outcomes compared to IV alteplase (tPA). The RESILIENT DIRECT-TNK trial will provide evidence to decide between bridging with TNK or direct MT for AIS due to LVO.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
RANDOMIZATION TO EXTEND STROKE INTRAVENOUS THROMBOLYSIS IN EVOLVING NON-LARGE VESSEL OCCLUSION WITH TNK (RESILIENT- EXTEND-IV) (GALLERY) - Nov 7, 2022 - Abstract #WSC2022WSC_1539;
In patients with AIS caused by large vessel occlusion (LVO) treated in the extended time window, with CTP selection, better outcomes were obtained with tenecteplase (TNK) versus tPA regarding arterial reperfusion and clinical outcomes... The RESILIENT EXTEND-IV trial may provide inputs on the efficacy and safety of TNK use in non-LVO AIS in the extended time window
- ||||| Aggrastat (tirofiban) / Correvio, Medicure, TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P4 trial: ATTIS: Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke (clinicaltrials.gov) - Nov 3, 2022
P4, N=600, Not yet recruiting, Sponsor: Second Affiliated Hospital of Guangxi Medical University
- |||||||||| GNR-060 (tenecteplase biosimilar) / Generium
New P3 trial: Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction (clinicaltrials.gov) - Nov 1, 2022
P3, N=244, Recruiting, Sponsor: AO GENERIUM
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Tenecteplase versus alteplase for early treatment of ischaemic stroke. (Pubmed Central) - Oct 28, 2022
The RESILIENT EXTEND-IV trial may provide inputs on the efficacy and safety of TNK use in non-LVO AIS in the extended time window No abstract available
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Tenecteplase versus alteplase for early treatment of ischaemic stroke - Authors' reply. (Pubmed Central) - Oct 28, 2022
No abstract available No abstract available
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Tranexamic acid for treatment of tenecteplase related hemorrhagic conversion. (Pubmed Central) - Oct 25, 2022
No abstract available No abstract available
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
PK/PD data, Journal: Population Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic Stroke. (Pubmed Central) - Oct 25, 2022
The PK characteristics of tenecteplase in patients with AMI were well described by the final model. Simulations from the model indicated that no specific dose recommendations based on covariates are warranted for AMI patients.
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
with such rapid administration, tenecteplase should even decrease time to brain clot (Twitter) - Oct 19, 2022
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: The promise of tenecteplase in acute stroke: Within reach or beyond approval? (Pubmed Central) - Oct 19, 2022
Increasing evidence supports tenecteplase as an alternative to alteplase, with many potential benefits. This article discusses the current state of the evidence for intravenous reperfusion and considers strategies for improving access, including possible modifications to efficacy-related regulatory updates.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Acute coronary syndrome with ST elevation at emergency department : Epidemiological Study () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_2010;
Mortality during Acute Coronary Syndrome with ST elevation remains high despite early and optimal management. Measures to combat cardiovascular risk factors must be considered to combat coronary heart disease.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Acute coronary syndrome with ST elevation at emergency department : Epidemiological Study () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_2009;
Mortality during Acute Coronary Syndrome with ST elevation remains high despite early and optimal management. Measures to combat cardiovascular risk factors must be considered to combat coronary heart disease.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Acute coronary syndrome with ST elevation at emergency department : Epidemiological Study () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_2008;
Mortality during Acute Coronary Syndrome with ST elevation remains high despite early and optimal management. Measures to combat cardiovascular risk factors must be considered to combat coronary heart disease.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Acute coronary syndrome with ST elevation at emergency department : Epidemiological Study () - Oct 17, 2022 - Abstract #EUSEM2022EUSEM_2007;
Mortality during Acute Coronary Syndrome with ST elevation remains high despite early and optimal management. Measures to combat cardiovascular risk factors must be considered to combat coronary heart disease.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Journal: Efficacy and safety of thrombolysis in COVID19 related ARDS. (Pubmed Central) - Oct 15, 2022
Measures to combat cardiovascular risk factors must be considered to combat coronary heart disease. In this unprecedented pandemic with high mortality rates, efficacy of early thrombolysis needs to be further explored in randomised controlled trials.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
New P2 trial: Additive Effects of Intra-arterial Tenecteplase for Successful Thrombectomy Due to Acute Basilar Artery Occlusion (clinicaltrials.gov) - Oct 14, 2022
P2, N=520, Not yet recruiting, Sponsor: First Hospital of China Medical University
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Comparative Effectiveness Of Routine Tenecteplase Thrombolysis In Acute Stroke Compared With Alteplase: An INternational Collaboration (CERTAIN Collaboration): Rates Of Symptomatic Intracranial Hemorrhage (Best of Specialty Conferences, Science and Technology Hall, Level 3; Poster Board no. 204) - Oct 5, 2022 - Abstract #AHA2022AHA_8131;
In this preliminary analysis from a large, multicenter registry, ischemic stroke treated with tenecteplase was associated with a lower rate of sICH than with alteplase. An updated analysis with patient data from additional sites will be presented at the Conference.
- | TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Comparison of door-to-needle time of tenecteplase versus alteplase for acute ischemic stroke. (Pubmed Central) - Oct 5, 2022
An updated analysis with patient data from additional sites will be presented at the Conference. No abstract available
- || TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review. (Pubmed Central) - Oct 4, 2022
We provide an overview of published clinical trials studying TNK in acute ischemic stroke, including dose-escalation studies and head-to-head comparisons with tPA. Finally, we summarize current acute stroke guideline recommendations and suggest treatment algorithms to manage the two main complications of intravenous thrombolysis: symptomatic intracerebral hemorrhage and angioedema.
- TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
EFFICACY AND SAFETY OF TENECTEPLASE IN MODERATE AND SEVERE ISCHEMIC STROKE: A POOLED ANALYSIS OF RANDOMIZED CLINICAL TRIALS - NOR-TEST 1 & 2 (Room 331) - Oct 1, 2022 - Abstract #WSC2022WSC_948;
For ischemic stroke with NIHSS⩾6, we found no difference in efficacy of the two thrombolytic agents, but mortality rates were higher in the tenecteplase group. A lower dose should be considered in future studies.